Air Liquide Q1 Revenue Misses Estimates Amid Currency and Energy Headwinds 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Toyota Global Vehicle Sales Decline in March Amid RAV4 Transition and Middle East Slowdown 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Google Secures Pentagon AI Deal for Classified Projects 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
Australia Targets Meta, Google, and TikTok With New News Payment Tax Proposal 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
Nippon Express Stock Jumps as Elliott Investment Signals Strong Foreign Interest in Japan Logistics Sector 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
BURLINGTON, Mass., Feb. 18, 2016 -- Flexion Therapeutics, Inc. (Nasdaq:FLXN) today announced that Michael Clayman, M.D., President and Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets 2016 Global Healthcare Conference on Tuesday, February 23, 2016 at 8:30 a.m. Eastern Time at the New York Palace Hotel in New York City.
To access the live webcast and subsequent archived recordings for the presentation, please visit the Flexion website at http://flexiontherapeutics.com/.
About Flexion Therapeutics
Flexion is a specialty pharmaceutical company focused on the development and commercialization of novel, local therapies for the treatment of patients with musculoskeletal conditions, beginning with OA. The company's lead product candidate, Zilretta, is being investigated for its potential to provide improved analgesic therapy for the millions of U.S. patients who receive IA injections for knee OA annually. The company is also investigating another product candidate, FX007, a locally administered TrkA receptor antagonist for post-operative pain.
Investor Contact David Carey Lazar Partners LTD T: 212-867-1768 [email protected] Media Contact Mariann Caprino TogoRun T : 917.242.1087 [email protected] Corporate Contact Fred Driscoll Chief Financial Officer Flexion Therapeutics, Inc. T: 781-305-7763 [email protected]
